Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
J Med Econ
; 20(8): 799-812, 2017 Aug.
Article
in En
| MEDLINE
| ID: mdl-28485692
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bone Diseases
/
Diphosphonates
/
Bone Density Conservation Agents
/
Denosumab
/
Imidazoles
/
Neoplasms
Type of study:
Clinical_trials
/
Health_economic_evaluation
Aspects:
Patient_preference
Limits:
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
En
Journal:
J Med Econ
Journal subject:
SERVICOS DE SAUDE
Year:
2017
Document type:
Article
Affiliation country:
Switzerland
Country of publication:
United kingdom